Montelukast in Chronic Asthma

Treatment of patients insufficiently treated with ICS or ICS + LABA.

Completed

Looking for future studies?

Key information

Conditions

Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients Insufficiently Treated With ICS Or ICS + LABA.

Treatment and study plan

Primary outcomes

Documentation of asthma control via ACT (Asthma Control Test).

Time frame: 6 months (12 months optional)

Secondary outcomes

Mini Asthma Quality of Life Questionnaire (Mini AQLQ).

Time frame: 6 months (12 months optional)

Sponsors and collaborators

Lead sponsor

Organon and Co

Industry

Registry information

Official study title

Montelukast in Chronic Asthma: Non-interventional Study With Montelukast 10 mg

Important dates

Study start: 2007
Primary completion: 2008
Study completion: 2008
First posted: Dec 5, 2008
Registry last updated: Feb 18, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed